民生銀行(600016.SH):成功發行300億元二級資本債券
格隆匯4月30日丨民生銀行(600016.SH)公佈,經國家金融監督管理總局和中國人民銀行批准,在全國銀行間債券市場成功發行了“中國民生銀行股份有限公司2024年第一期二級資本債券”,並在銀行間市場清算所股份有限公司完成債券的登記、託管。
本期債券於2024年4月25日簿記建檔,並於2024年4月29日完成發行。發行規模為人民幣300億元,債券為10年期固定利率債券,在第5年末附有條件的發行人贖回權,票面利率為2.50%。本期債券募集資金將依據適用法律和監管部門的批准,用於補充本行二級資本,提高資本充足率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.